2026.03.22 (일)

  • 흐림동두천 2.7℃
  • 흐림강릉 10.4℃
  • 흐림서울 5.5℃
  • 흐림대전 4.3℃
  • 흐림대구 6.6℃
  • 흐림울산 6.7℃
  • 흐림광주 6.0℃
  • 흐림부산 10.7℃
  • 흐림고창 1.6℃
  • 구름많음제주 8.8℃
  • 흐림강화 2.9℃
  • 흐림보은 1.1℃
  • 흐림금산 1.4℃
  • 흐림강진군 3.5℃
  • 흐림경주시 4.0℃
  • 흐림거제 6.9℃
기상청 제공

경제

Harmony(TM) Prenatal Test Demonstrates Clinical Utility in a General Screening Population

[By NBC-1TV H. J Yook]The Harris Birthright Centre for Fetal Medicine today released results from a clinical implementation study (http://onlinelibrary.wiley.com/doi/10.1002/uog.125...) on the use of Ariosa Diagnostics' Harmony™ Prenatal Test in a general screening population. The test uses cell-free DNA (cfDNA) testing from maternal blood to assess fetal genetic conditions such as trisomy 21, which causes Down syndrome. The study looked at the feasibility, reliability and utility of performing the test in a general screening population, not just for high-risk pregnancies, and demonstrated that cfDNA testing can be safely incorporated into routine prenatal care to reduce unnecessary invasive testing, like amniocentesis.

Professor Kypros Nicolaides, a renowned maternal fetal medicine specialist and one of the authors of the study, said, “The results of our study demonstrate the value of cfDNA testing in routine screening for trisomies. This technology represents one of the greatest advances in prenatal screening and can help guide better management for any pregnant woman.”



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너